SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study will investigate whether the simplified regimen of a once daily fixed dose
combination of Truvada (emtricitabine and tenofovir disoproxil fumarate [DF]) will be
associated with a reduced rate of adverse events, seen with long term use of antiretrovirals,
as well as improved adherence compared to a twice daily fixed dose combination of Combivir.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Lamivudine Lamivudine, zidovudine drug combination Tenofovir Zidovudine